Dr. Richard Isaacson was featured in The Wall Street Journal discussing the future of Alzheimer’s prevention for people at high genetic risk of developing early-onset Alzheimer’s disease. The article examines groundbreaking research exploring whether anti-amyloid therapies can delay or even prevent symptoms before they begin, while highlighting the promise and complexity of treating individuals who have not yet developed clinical signs of the disease.

Dr. Isaacson provided expert perspective on the importance of balancing scientific innovation with careful clinical decision-making as researchers continue to evaluate preventive treatments for those at the highest risk of Alzheimer’s disease.

Read the full Wall Street Journal article to learn more about this emerging area of Alzheimer’s research and the efforts to intervene before symptoms appear.